Sign in Subscribe
Universities and colleges

Harnessing the Power of Langerhans Cells for Immunotherapy

Strategic Insights

— 1 min read

Researchers in Innsbruck, Austria have made significant progress in understanding the potential of Langerhans cells, a subset of skin dendritic cells, for immunotherapy. These cells play a crucial role in surveying peripheral tissue for invading pathogens and can present exogenous antigen to CD4+ and CD8+ T cells. A recent study has shown that Langerhans cells can be targeted with antigenic proteins, leading to potent in vivo proliferative responses of CD4+ and CD8+ T cells. This breakthrough has significant implications for the development of new immunotherapy strategies.

Key Takeaways:

  • Langerhans cells, a subset of skin dendritic cells, can present exogenous antigen to both CD4+ and CD8+ T cells.
  • Topical application of antigenic proteins is sufficient to induce potent in vivo proliferative responses of CD4+ and CD8+ T cells.
  • Langerhans cells are the main skin dendritic cell subset transporting antigen during emigration from skin explants.
  • Targeting antibodies against DEC-205/CD205 and langerin/CD207 are mainly transported by migratory Langerhans cells.
  • The preferential capture of topically applied antigen by Langerhans cells emphasizes their potential for epicutaneous immunization strategies.
  • The study highlights the potential of Langerhans cells for immunotherapy, which could be developed into new treatment strategies for cancer patients.

Statistics:

  • 58% of skin dendritic cells are Langerhans cells, which play a crucial role in surveying peripheral tissue for invading pathogens. (Cancer Immunology, Immunotherapy, 2009;58(7):1137-47)
  • The study reported potent in vivo proliferative responses of CD4+ and CD8+ T cells after epicutaneous immunization with low amounts of protein antigen. (Cancer Immunology, Immunotherapy, 2009;58(7):1137-47)
  • The researchers applied either fluorescently labeled protein antigen or targeting antibodies against DEC-205/CD205 and langerin/CD207 topically onto barrier-disrupted skin in the current study. (Cancer Immunology, Immunotherapy, 2009;58(7):1137-47)

Sources:

  • Flacher, V., et al. "Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy." Cancer Immunology, Immunotherapy 58.7 (2009): 1137-1147.
  • Cancer Vaccine Week editors. "Cancer Immunology, Immunotherapy." NewsRx.com, 2009.

Read more